MARKET

CNTB

CNTB

Connect Biopharma Holdings Ltd
NASDAQ
2.550
+0.010
+0.39%
After Hours: 2.520 -0.03 -1.16% 19:34 08/14 EDT
OPEN
2.540
PREV CLOSE
2.540
HIGH
2.570
LOW
2.360
VOLUME
212.18K
TURNOVER
--
52 WEEK HIGH
3.820
52 WEEK LOW
1.230
MARKET CAP
160.58M
P/E (TTM)
-2.2103
1D
5D
1M
3M
1Y
5Y
1D
Connect Biopharma Holdings Limited's non-GAAP EPS of -$0.27 misses by $0.04, and revenue of $2.77M beats by $1.9M
Seeking Alpha · 1d ago
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB) and Biomea Fusion (BMEA)
TipRanks · 1d ago
Buy Rating Reiterated on CNTB as Clinical Derisking Looms and Risk/Reward Remains Attractive; $10 Price Target Maintained
TipRanks · 1d ago
Weekly Report: what happened at CNTB last week (0803-0807)?
Weekly Report · 4d ago
Weekly Report: what happened at CNTB last week (0727-0731)?
Weekly Report · 08/03 10:26
Weekly Report: what happened at CNTB last week (0720-0724)?
Weekly Report · 07/27 10:31
Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent
Seeking Alpha · 07/23 06:15
Weekly Report: what happened at CNTB last week (0713-0717)?
Weekly Report · 07/20 10:27
More
About CNTB
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

Webull offers Connect Biopharma Holdings Ltd (ADR) stock information, including NASDAQ: CNTB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNTB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNTB stock methods without spending real money on the virtual paper trading platform.